Patents by Inventor Maiko Hamada
Maiko Hamada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11890288Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.Type: GrantFiled: July 20, 2023Date of Patent: February 6, 2024Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kiyomi Ohba, Yasuki Niwa, Tetsuji Matsudaira, Maiko Hamada, Ryuta Yamazaki, Tatsuya Ibuki
-
Publication number: 20230364105Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.Type: ApplicationFiled: July 20, 2023Publication date: November 16, 2023Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kiyomi OHBA, Yasuki NIWA, Tetsuji MATSUDAIRA, Maiko HAMADA, Ryuta YAMAZAKI, Tatsuya IBUKI
-
Patent number: 11802135Abstract: The present invention aims to provide a compound acting as a specific agonist for LPA4 receptors, and a pharmaceutical composition containing the compound. The present invention relates to a novel lysophosphatidic acid derivative having an agonistic action on LPA4 receptors and useful for the prophylaxis and/or treatment of diseases associated with angiogenesis abnormalities involving LPA4 receptors, diseases associated with vascular disorders, or the symptoms associated therewith, and a pharmaceutical composition containing the derivative.Type: GrantFiled: November 3, 2021Date of Patent: October 31, 2023Assignees: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITYInventors: Maiko Hamada, Yuki Arai, Shuhei Yamakoshi, Hiroko Wada, Kazufumi Otsuki, Hiroaki Shitama, Nobuyuki Takakura
-
Publication number: 20230146717Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.Type: ApplicationFiled: February 5, 2021Publication date: May 11, 2023Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kiyomi OHBA, Yasuki NIWA, Tetsuji MATSUDAIRA, Maiko HAMADA, Ryuta YAMAZAKI, Tatsuya IBUKI
-
Publication number: 20230146210Abstract: The present invention aims to provide a compound acting as a specific agonist for LPA4 receptors, and a pharmaceutical composition containing the compound. The present invention relates to a novel lysophosphatidic acid derivative having an agonistic action on LPA4 receptors and useful for the prophylaxis and/or treatment of diseases associated with angiogenesis abnormalities involving LPA4 receptors, diseases associated with vascular disorders, or the symptoms associated therewith, and a pharmaceutical composition containing the derivative.Type: ApplicationFiled: November 3, 2021Publication date: May 11, 2023Applicants: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITYInventors: Maiko HAMADA, Yuki ARAI, Shuhei YAMAKOSHI, Hiroko WADA, Kazufumi OTSUKI, Hiroaki SHITAMA, Nobuyuki TAKAKURA
-
Patent number: 11542273Abstract: Provided are a compound superior in a cytotoxic action on cancer cells, an action inducing degradation of BET protein in cancer cells, and an inhibitory action on the binding of BET protein and acetylated histone, and useful as an anticancer agent, a BET protein degradation inducer or a BET protein inhibitor. A compound represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof.Type: GrantFiled: July 4, 2019Date of Patent: January 3, 2023Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Ryuta Yamazaki, Tatsuya Ibuki, Yuichi Sawaguchi, Kiyomi Ohba, Maiko Hamada, Yasuki Niwa, Yuko Ishida, Hideto Maruyama, Shiki Matsuki, Minoru Tanaka
-
Publication number: 20210284654Abstract: Provided are a compound superior in a cytotoxic action on cancer cells, an action inducing degradation of BET protein in cancer cells, and an inhibitory action on the binding of BET protein and acetylated histone, and useful as an anticancer agent, a BET protein degradation inducer or a BET protein inhibitor.Type: ApplicationFiled: July 4, 2019Publication date: September 16, 2021Applicants: MITSUBISHI TANABE PHARMA CORPORATION, KABUSHIKI KAISHA YAKULT HONSHAInventors: Ryuta YAMAZAKI, Tatsuya IBUKI, Yuichi SAWAGUCHI, Kiyomi OHBA, Maiko HAMADA, Yasuki NIWA, Yuko ISHIDA, Hideto MARUYAMA, Shiki MATSUKI, Minoru TANAKA
-
Patent number: 10407408Abstract: Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.Type: GrantFiled: July 8, 2016Date of Patent: September 10, 2019Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Seigo Ishibuchi, Kunio Saruta, Maiko Hamada, Nobuatsu Matoba, Tetsuji Matsudaira, Maki Seki, Akiko Tarao, Takashi Honjo, Shingo Ogata, Atsushi Kawata, Kenji Morokuma, Naoto Fujie, Yukio Aoyama
-
Publication number: 20190077787Abstract: Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.Type: ApplicationFiled: July 8, 2016Publication date: March 14, 2019Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Seigo ISHIBUCHI, Kunio SARUTA, Maiko HAMADA, Nobuatsu MATOBA, Tetsuji MATSUDAIRA, Maki SEKI, Akiko TARAO, Takashi HONJO, Shingo OGATA, Atsushi KAWATA, Kenji MOROKUMA, Naoto FUJIE, Yukio AOYAMA
-
Patent number: 9657043Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.Type: GrantFiled: April 23, 2013Date of Patent: May 23, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Maiko Hamada, Kaoru Tashiro, Hiroshi Sakashita, Masatoshi Kiuchi, Shuzo Takeda, Kunitomo Adachi
-
Patent number: 9527859Abstract: The present invention relates to novel amidopyridine derivatives. More specifically, the present invention provides a medicinal agent which is useful as a prophylactic or therapeutic agent for diseases based on the production of cytokines from T cells, comprising as the active ingredient an amidopyridine derivative or a pharmacologically acceptable salt thereof. Provided are an amidopyridine derivative of the following general formula (I): wherein each symbol has the same meaning as defined in the description, or a pharmacologically acceptable salt thereof.Type: GrantFiled: April 12, 2013Date of Patent: December 27, 2016Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Masayuki Watanabe, Hiroyuki Furukawa, Maiko Hamada, Naoto Fujie, Hiroyuki Ushio, Tooru Takashima
-
Patent number: 9150555Abstract: The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T cells, and which comprises an amide derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or the pharmacologically acceptable salt as an active ingredient. Provided is an amide derivative represented by general formula (I) [wherein each symbol is as defined in the description] or a pharmacologically acceptable salt thereof, or a solvate of the derivative or the pharmacologically acceptable salt.Type: GrantFiled: October 13, 2011Date of Patent: October 6, 2015Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Hiroyuki Ushio, Maiko Hamada, Masayuki Watanabe, Atsushi Numata, Naoto Fujie, Tooru Takashima, Hiroyuki Furukawa, Junki Ando
-
Publication number: 20150087620Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.Type: ApplicationFiled: April 23, 2013Publication date: March 26, 2015Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Maiko Hamada, Kaoru Tashiro, Hiroshi Sakashita, Masatoshi Kiuchi, Shuzo Takeda, Kunitomo Adachi
-
Publication number: 20150065715Abstract: The present invention relates to novel amidopyridine derivatives. More specifically, the present invention provides a medicinal agent which is useful as a prophylactic or therapeutic agent for diseases based on the production of cytokines from T cells, comprising as the active ingredient an amidopyridine derivative or a pharmacologically acceptable salt thereof. Provided are an amidopyridine derivative of the following general formula (I): wherein each symbol has the same meaning as defined in the description, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: April 12, 2013Publication date: March 5, 2015Applicant: Mitsubishi Tanabe Pharma CorporationInventors: Masayuki Watanabe, Hiroyuki Furukawa, Maiko Hamada, Naoto Fujie, Hiroyuki Ushio, Tooru Takashima
-
Publication number: 20130211075Abstract: The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T cells, and which comprises an amide derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or the pharmacologically acceptable salt as an active ingredient. Provided is an amide derivative represented by general formula (I) [wherein each symbol is as defined in the description] or a pharmacologically acceptable salt thereof, or a solvate of the derivative or the pharmacologically acceptable salt.Type: ApplicationFiled: October 13, 2011Publication date: August 15, 2013Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hiroyuki Ushio, Maiko Hamada, Masayuki Watanabe, Atsushi Numata, Naoto Fujie, Tooru Takashima, Hiroyuki Furukawa, Junki Ando
-
Patent number: 8129361Abstract: Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.Type: GrantFiled: June 13, 2008Date of Patent: March 6, 2012Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Masatoshi Kiuchi, Kaoru Tashiro, Maiko Hamada, Kunio Sugahara
-
Patent number: 8114902Abstract: Disclosed is a 2-aminobutanol compound represented by the following formula (I) or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof, as well as a production method of the 2-aminobutanol compound of formula (I). The 2-aminobutanol compounds of formula (I) have few side effects including bradycardia and have superior peripheral blood lymphocyte-decreasing effects.Type: GrantFiled: April 27, 2007Date of Patent: February 14, 2012Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Masatoshi Kiuchi, Mitsuharu Nakamura, Maiko Hamada, Kunio Sugahara
-
Patent number: 8044042Abstract: A thienotriazolodiazepine compound of the following formula (I) a pharmaceutical agent containing the compound as an active ingredient, and a production intermediate and a production method of the thienotriazolodiazepine compound. Since this compound has an inhibitory action on costimulatory signal from CD28 on T cell, it is useful for the prophylaxis or suppression of rejection reaction in transplantation of organ or bone marrow and the like, and the prophylaxis or treatment of autoimmune diseases or allergic diseases.Type: GrantFiled: May 30, 2006Date of Patent: October 25, 2011Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Kunitomo Adachi, Hidemasa Hikawa, Maiko Hamada, Jun-ichi Endoh, Seigo Ishibuchi, Naoto Fujie, Minoru Tanaka, Kunio Sugahara, Kouichi Oshita, Meguru Murata
-
Patent number: 7935700Abstract: A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.Type: GrantFiled: September 8, 2005Date of Patent: May 3, 2011Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Yoshihito Tanaka, Shuzo Takeda, Hidemitsu Higashi, Mamoru Matsuura, Fujio Kobayashi, Maiko Hamada, Minoru Tanaka
-
Publication number: 20100179216Abstract: Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.Type: ApplicationFiled: June 13, 2008Publication date: July 15, 2010Inventors: Masatoshi Kiuchi, Kaoru Tashiro, Maiko Hamada, Kunio Sugahara